What Is Metaplastic Triple-Negative Breast Cancer?

Metaplastic triple-negative breast cancer is an uncommon and aggressive form of breast cancer in which tumor cells transform into cell types not normally found in breast tissue, such as spindle-shaped cells, squamous (skin-like) cells, or even bone and cartilage-like tissue. It accounts for less than one percent of all invasive breast cancers and is classified as triple-negative because the tumor cells almost always lack the three receptors that drive most breast cancers: estrogen receptor, progesterone receptor, and HER2.¹ That triple-negative status matters because it eliminates the most commonly used hormonal and HER2-targeted treatments from the playbook, and metaplastic tumors layer on an additional problem: they tend to resist standard chemotherapy far more stubbornly than other triple-negative breast cancers.

How It Differs from Ordinary Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) itself is already considered harder to treat than hormone-receptor-positive or HER2-positive breast cancers, because fewer targeted drugs apply. Metaplastic breast cancer (often abbreviated MBC or MpBC) sits within the triple-negative category but behaves worse on nearly every metric. In a large comparison study, patients with metaplastic tumors had a five-year overall survival of about 56%, compared with 72% for those with conventional TNBC.² Another analysis found that metaplastic histology was linked to significantly worse three-year progression-free survival (roughly 51% versus 82%) and overall survival (about 68% versus 94%) compared with TNBC.³

The survival gap comes partly from biology and partly from the tumor’s stubbornness against the chemotherapy regimens that work reasonably well for other triple-negative cancers. Metaplastic tumors show deregulated immune responses and altered extracellular structures compared with ordinary TNBC, and the different tissue subtypes within metaplastic cancer each display their own distinct molecular processes.⁴

What “Metaplastic” Actually Means Under the Microscope

The term “metaplastic” describes a process where breast cancer cells that would ordinarily look like glandular (ductal) tissue instead take on entirely different identities. Under a microscope, a pathologist might see squamous cells that resemble skin, spindle-shaped cells that look like connective tissue, or even patches that resemble cartilage or bone. A single tumor can contain a mixture of these elements, which is part of what makes diagnosis tricky. The defining feature is the presence of adenocarcinoma mixed with at least one of these non-glandular tissue types.¹

The subtypes matter because they behave somewhat differently. Squamous subtypes show enriched skin-cell-like processes, spindle cell subtypes are driven by protein-breakdown pathways, and sarcomatoid subtypes show heightened immune cell activation.⁴ This biological diversity within one disease category is one reason it has been so difficult to develop a single effective treatment approach.

Who Gets It and How Common Is It

Metaplastic breast cancer is rare enough that most oncologists will see only a handful of cases over a career. Population data from the United States SEER cancer registry have tracked over 5,000 cases diagnosed between 2000 and 2018, which sounds like a lot until you compare it with the hundreds of thousands of ordinary ductal carcinoma cases over the same period.⁵ An earlier SEER analysis found roughly 1,000 metaplastic cases versus over 250,000 invasive ductal carcinoma cases over a decade.⁶

Interestingly, incidence appears to be climbing. A population-based study found the age-adjusted incidence rate rose from about 0.12 to 0.35 per 100,000 people over the study period, which translates to an annual increase of roughly 3%.⁷ Whether that reflects a genuine increase in the disease or improved recognition and classification by pathologists is an open question. Better awareness of metaplastic subtypes and more widespread use of immunohistochemistry for diagnosis have almost certainly contributed to the uptick.

How It Presents and Gets Diagnosed

Metaplastic breast cancers are generally fast growers. They tend to show up as a rapidly enlarging, palpable lump.⁸ On a mammogram, the mass typically appears dense and well-defined without calcifications, which can actually make it look deceptively benign. Ultrasound often reveals a more complex picture: a mixture of solid and cystic areas, reflecting the necrosis and degeneration that occur inside these tumors. An MRI may show high signal on certain sequences because of those same necrotic and cystic components.⁹ The imaging appearance can mimic both ordinary invasive ductal carcinoma and even benign lesions, so a tissue biopsy is essential for accurate diagnosis.

Under the microscope, pathologists use specific markers to confirm the diagnosis. A protein called p63 has proven particularly useful. One study found p63 was strongly expressed in about 87% of metaplastic carcinomas, while less than 1% of non-metaplastic breast cancers tested positive for it, giving it very high specificity.¹⁰ Combining p63 with other markers, such as OSCAR (a cytokeratin marker) and wide-spectrum cytokeratin, can boost both the sensitivity and specificity of the diagnosis further.¹¹ Getting the pathology right matters because the treatment implications are different from those of a standard triple-negative tumor.

The Biology Behind the Shape-Shifting

The leading explanation for why these cancer cells take on such unusual forms centers on a process called epithelial-to-mesenchymal transition, or EMT. In normal development, EMT is how tightly packed epithelial cells loosen up and become mobile, a process that plays a critical role in wound healing and embryonic development. In metaplastic breast cancer, the same machinery gets hijacked by the tumor. Cancer cells shed their normal epithelial identity and acquire properties of mesenchymal cells: they become more mobile, more invasive, and harder to kill with standard drugs.¹²

Growing evidence supports the idea that EMT is central to metaplastic breast cancer’s development, and that it may explain both the tissue transformation and the chemotherapy resistance that clinicians observe.¹³ When cells undergo EMT, they also tend to become more stem-cell-like, which may be why these tumors are so difficult to eradicate entirely: even aggressive chemotherapy that kills the bulk of the tumor can leave behind drug-resistant, stem-like cells that eventually regrow.

Genomic Drivers and Why They Matter for Treatment

Genomic profiling of metaplastic breast cancers has revealed a distinct mutational landscape that sets them apart from other triple-negative tumors and creates potential openings for targeted therapy. The most frequently altered gene is TP53, mutated in roughly two-thirds to nearly 90% of cases depending on the study.¹⁴ TP53 is a tumor-suppressor gene, and its loss essentially removes a key brake on cancer cell growth.

More actionable, though, are the mutations in the PI3K/AKT/mTOR pathway. Metaplastic carcinomas harbor PIK3CA mutations or related pathway alterations at strikingly high rates compared with other triple-negative cancers. One genomic profiling study found PI3K-pathway alterations in about 61% of metaplastic tumors versus just 14% in the general triple-negative cancer dataset.¹⁵ Another analysis confirmed that over half of metaplastic cancers carried mutations in PI3K/AKT/mTOR pathway genes, significantly more than the roughly 22% seen in non-metaplastic triple-negative tumors. Mutations in Wnt pathway genes were also more common.¹⁶

The PI3K pathway is significant because drugs targeting it already exist for other cancers. These mutations are also “truncal,” meaning they appear early in the tumor’s evolution and persist across metastatic sites, suggesting they are fundamental drivers rather than bystander mutations that come and go.¹⁴

Why Standard Chemotherapy Often Falls Short

One of the most frustrating aspects of metaplastic triple-negative breast cancer is its poor response to the chemotherapy regimens that are standard for other triple-negative tumors. In the neoadjuvant setting, where chemotherapy is given before surgery to shrink the tumor, the results are dismal. One cohort study found a pathological complete response rate of just 2%, meaning that in 44 patients treated with standard neoadjuvant chemotherapy, only a single patient had no tumor left at surgery.¹⁷ A larger prospective analysis found metaplastic tumors achieved complete response at about 23% compared with 40% for non-metaplastic TNBC, though the difference narrowly missed statistical significance due to small sample sizes.¹⁸

Clinicians have tried various chemotherapy combinations, including ifosfamide-based regimens, but the results remain largely disappointing. Metaplastic tumors often progress despite treatment, and there are no well-defined standard chemotherapy protocols specifically for this subtype.¹⁹ The chemoresistance is thought to be linked to the same EMT biology that gives these tumors their unusual appearance: cells that have undergone EMT are inherently harder to kill with conventional cytotoxic drugs.

Where It Spreads

When metaplastic breast cancer does metastasize, it shows a somewhat different pattern than ordinary breast cancer. The lungs are the most common site of distant spread, followed by bone and then brain.²⁰ The relative preference for lungs over bone is notable because most breast cancers favor bone metastasis first. This lung-dominant pattern may relate to the mesenchymal and sarcoma-like characteristics of metaplastic tumors, which in some ways behave more like soft-tissue sarcomas than typical carcinomas. Lymph node involvement at diagnosis is less common in metaplastic cancer than in regular TNBC, which creates a paradox: these tumors can spread to distant organs through the bloodstream even when lymph nodes appear clean.

Surgery and Radiation

Surgical treatment follows the same basic principles as for other breast cancers: either lumpectomy (removing the tumor with a margin of normal tissue) or mastectomy (removing the entire breast). In a large national database study of over 5,200 patients, mastectomy was the more common choice, used in about 56% of cases, and most patients received chemotherapy.²¹

Radiation after surgery appears to provide meaningful benefit, especially for patients with higher-risk disease. After lumpectomy, adding radiation was associated with improved overall survival regardless of tumor size or node status. After mastectomy, the benefit of radiation was clearest for patients with larger tumors or positive lymph nodes.²¹ A SEER-based study found that post-mastectomy radiation roughly halved the risk of breast-cancer-specific death in both intermediate-risk and high-risk groups.²² For patients at lower risk (small tumors, no lymph node involvement), the radiation benefit after mastectomy was less clear.²³

Immunotherapy as a Promising Avenue

Perhaps the most encouraging development in metaplastic breast cancer treatment has come from immunotherapy. Metaplastic tumors express the immune checkpoint protein PD-L1 at remarkably high rates. One study using established scoring criteria found that the vast majority of metaplastic tumors were PD-L1-positive (ranging from 86% to 95% depending on the assay), compared with roughly 41% of conventional TNBC.²⁴ This means most patients with metaplastic breast cancer are at least potentially eligible for anti-PD-L1 or anti-PD-1 therapy.

Case reports have documented dramatic responses. One patient with a high-grade, triple-negative, PD-L1-positive metaplastic tumor achieved a complete pathological response after neoadjuvant treatment combining pembrolizumab with standard chemotherapy.²⁵ In another case, a patient who had been progressing on chemotherapy alone saw rapid eradication of a large tumor and visceral metastases after adding pembrolizumab, with evidence suggesting the immunotherapy was driving the response rather than the chemotherapy.²⁶ These remain individual cases rather than large-trial evidence, but the biological rationale is strong, and the consistency of the PD-L1 expression data supports further investigation.

Targeted Therapies and Antibody-Drug Conjugates

The high frequency of PI3K-pathway mutations has led to early trials of targeted drugs in metaplastic breast cancer. In a study of PI3K/AKT/mTOR-directed therapy, about a quarter of treated patients showed a response, and all patients who benefited had tumors carrying an activation-related alteration in that pathway.²⁷ A particularly striking case involved a patient with a genetic syndrome that causes PTEN loss (a gene that normally restrains the PI3K pathway): she achieved disease stabilization lasting nearly four years on a novel AKT inhibitor called TAS-117 after failing multiple previous treatment lines.²⁸

Antibody-drug conjugates represent another new frontier. Sacituzumab govitecan, which is already approved for metastatic triple-negative breast cancer, has shown early promise specifically in metaplastic cases. One report documented a sustained clinical response lasting close to a year in a patient with metastatic metaplastic breast cancer who had failed multiple prior lines of therapy, including immunotherapy.²⁹ Another case report described a complete metabolic response, meaning no detectable tumor on PET scan, with sacituzumab govitecan in a patient who had been resistant to anthracycline, taxane, platinum, and pembrolizumab.³⁰ These early results are based on individual cases, not randomized trials, but they offer real hope for a disease that has historically resisted nearly everything thrown at it.

The Role of Genomic Profiling and Liquid Biopsy

Given the distinct genomic landscape of metaplastic breast cancer, genomic profiling of the tumor at diagnosis is increasingly viewed as critical. Identifying PI3K-pathway mutations, TP53 status, and other actionable alterations can open doors to targeted treatments or clinical trials that would otherwise be missed. This is especially important because metaplastic tumors are genetically heterogeneous. Even within a single tumor, different areas can carry different mutations, and the mutational profile can shift as the cancer evolves and spreads.¹⁴

Circulating tumor DNA, often called a liquid biopsy, is an emerging tool that could be particularly useful for monitoring metaplastic breast cancer. Rather than requiring a new tissue biopsy every time a treatment decision needs to be updated, a blood draw can detect DNA shed by tumor cells. Early data in breast cancer generally suggest that circulating tumor DNA can detect disease progression months before imaging catches it, and it may help guide decisions about treatment changes after initial therapy.³¹ For a cancer as rare and heterogeneous as metaplastic breast cancer, the ability to track the tumor’s evolving genetic profile in real time could eventually become essential for guiding the kind of personalized treatment approaches this disease demands.

Navigating a Rare Diagnosis

Because metaplastic triple-negative breast cancer is so uncommon, there are no dedicated large-scale randomized trials that have tested treatment regimens specifically for this disease. Most management decisions are guided by extrapolation from triple-negative breast cancer trials, case series, retrospective database studies, and expert consensus. A multidisciplinary approach involving surgical oncology, medical oncology, radiation oncology, and pathology is strongly recommended, and some experts suggest seeking care at centers with specific experience treating rare breast cancer subtypes.³²

Patients diagnosed with metaplastic breast cancer should ask about genomic profiling of their tumor and PD-L1 testing, as both can expand the range of treatment options. Requesting a second opinion on pathology is also reasonable, given the difficulty of distinguishing metaplastic subtypes and the implications for treatment planning. Clinical trials are worth actively seeking out: disease-specific trials and reports of exceptional individual responses are the main engines driving progress for this cancer, and enrollment benefits both the patient and the broader community of patients who share this rare diagnosis.³³